Pharma companies may not like their products being the subject of ICER reports, but they can provide a jumping-off point for manufacturers to expand the conversation of the value of new medicines in the rare disease area.
The healthcare ad industry continues to thrive and adapt to the new demands for relevance and creativity.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The Medical Advertising Hall of Fame honored 2019 inductees Carol DiSanto and Charlene Prounis on Feb. 7th at The Pierre in New York City.
The threatened “pharma marketing tax” may be back in play during 2019, at both the federal and state levels.
The U.S. Department of Health and Human Services (HHS) is considering proposing a plan that has many moving parts, one of which could potentially take the price that Medicare pays out to providers for Medicare Part B drugs and turn it on its head.
The talent and tenacity of immigrants can help drive the life sciences industry into the future, if we have the will and the wisdom to encourage it.
For the tenth year, Med Ad News chose new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
GSW, an INC Research/inVentiv Health company and industry leader in healthcare advertising, named Sonja Foster-Storch as president. Foster-Storch reports to Lisa Stockman, president of inVentiv Health Communications.
Two Omnicom Health Group agencies will have new leadership as of January 1, 2018. Mario Muredda was named CEO of Harrison and Star, and Kristin Kantak will be CEO of Biolumina.
The Inception Companies appointed Matt Giegerich, longtime CEO of WPP’s Ogilvy CommonHealth, to serve as CEO for Inception’s two largest business units.
HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.
The marketplace is changing. It has become cliché to say it. In fact, for years the healthcare market access space has been under pressure to evolve, grow, and reinvent itself – all while digging in its heels and clinging to a vanishing status quo.
Access to treatments for rare diseases depends on a delicate balance of a price that allows for the development of innovative therapies while also being considered “affordable.” A low price for a manufacturer’s therapy would discourage potential developers from focusing their future efforts on new therapies because of a limited return on investments. At the opposite end of the spectrum are barriers to access based on a price that is considered cost prohibitive; utilization is limited in an effort to control costs. The balance between these 2 opposing access decision-making contingencies will determine the degree to which patients with rare diseases will receive the treatments they need.
In healthcare, we are fortunate to have access to code that analyzes data and provides us with customer insights. As marketers, we can now understand these individual customers better than ever before. We know what we need and want to do when it comes to reaching them. But what does all that power and possibility do for them?
The healthcare industry is ever evolving and today’s patients are far more engaged than the previous era of “doctor knows best.” Increasingly, not only are patients involved in managing their day-to-day health, they and their fellow patients, caregivers, and advocates are driving the progress of drug treatments from discovery to delivery as well.
Consumer/Patient Experience Special Feature: Protecting the Patient Experience in the Age of Mega-Mergers
Consolidation has dominated healthcare news over the past few years. Mergers between hospitals, payers, clinics, and other healthcare organizations are turning an ecosystem of individual stakeholders into one dominated by a few giants.
From Isolation to Anticipation: How technology continues to improve the lives of rare disease families
Working in the rare disease space has never been more rewarding than it is today. Technology is turning what was once thought to be impossible into actual, tangible realities for physicians, patients, and families. There are many exciting advancements happening now – in real time – and even more on the horizon that demand our attention and advocacy to help bring them to light.
The first rule of rare: There are no rules. There are over 7,000 different rare diseases – each with its own symptomology, history, and clinical and political landscape. Most are virgin territory for marketers; only 5 percent have an approved treatment.